CRSP at a glance
CRISPR Therapeutics AG (CRSP, SEC CIK 1674416) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CRISPR Therapeutics AG (CRSP) reported revenue of $3.5 million (down 90.6% from FY2024) and a net loss of $581.6 million. Diluted EPS was -$6.47.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding CRISPR Therapeutics AG (CRSP) shares worth $1.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KASINGER JAMES R. on September 22, 2026 of 10,400 shares at $60.24 per share.
- In the last 90 days, CRSP insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.5M
- −90.6% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.4M
- 13F holders
- 35 funds
- $1.9B · +3 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
- Strategic shift: Increased focus on in vivo editing pipeline using proprietary SyNTase technology and LNP delivery to target liver and other tissues, alongside advancing siRNA programs via Sirius partnership
- Quantitative metric: CASGEVY approved in multiple countries, addressing an estimated 60,000 patients; pediatric pivotal studies show 100% efficacy in vaso-occlusive crisis and transfusion independence endpoints
- Noteworthy fact: CASGEVY is the world’s first approved CRISPR-based gene therapy, representing a major milestone and shifting CRISPR Therapeutics from R&D to commercial-stage biopharma firm
Risk Factors
- Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
- Operational vulnerability: Dependence on third-party manufacturers and supply chain to establish clinical and commercial product supply capacity
- Competitive risk: Other gene editing firms' ex vivo/in vivo therapies may trigger additional FDA requirements delaying CRISPR Therapeutics’ programs
- Financial risk: Cash $1,975.8M as of Dec 31, 2025 sufficient for 24 months, but substantial capital raises required thereafter, diluting shareholders
Management Discussion & Analysis
- Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
- Investing cash flow used $31.8M in 2025 vs $280.5M in 2024, improvement driven by marketable debt securities maturities in 2025
- Financing cash flow provided $426.0M in 2025 vs $332.0M in 2024, mainly from $397.3M ATM common shares sale and $27.7M stock option proceeds
- Outlook: Cash sufficient to fund operations 24 months; dependency on equity/debt financing; risks include volatile markets, regulatory approval uncertainties, and commercial execution
AI summary of the CRSP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $10.181M, up $9.289M YoY from $892K
- Net loss $91.154M vs $208.549M YoY
- Operating loss $117.269M vs $229.324M YoY
- Operating expenses $127.450M, down $102.766M YoY
- Collaboration revenue $10.0M from license upfront payment; no comparable 2025 revenue
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures only
- New executive trading plans through May 31, 2027, covering 93,632 and 14,565 common shares
- New 2026 Stock Option and Incentive Plan, filed June 4, 2026, creating potential equity-compensation dilution
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed in the provided text
AI summary of the CRSP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- CRISPR Therapeutics reported financial results for quarter ended June 30, 2026
- Business highlights and detailed financial figures contained in furnished Exhibit 99.1
Item EX-99.1: Item EX-99.1
- CASGEVY revenue reached $76 million, up 78% quarter-over-quarter and 151% year-over-year, strengthening commercial validation
- FDA approval for patients aged 2 and older expands potential eligibility by approximately 5,500 SCD or TDT patients
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Shareholders approved amended and restated Articles of Association at the June 4, 2026 Annual Meeting
- Amendments effective upon Zug Commercial Register registration, subject to Swiss Federal Commercial Authority approval
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved the 2026 Stock Option and Incentive Plan on June 4, 2026
- New plan carries forward remaining 2018 Plan shares plus shares from forfeited or canceled awards
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders approved 2025 financial statements, loss carryforward, director discharge, and all 11 board re-elections, preserving governance continuity
- Capital-band expansion and conditional share-capital increase approved, strengthening financing and potential convertible-debt flexibility
Item 2.02: Results of Operations and Financial Condition
- CRISPR Therapeutics reported financial results for quarter ended March 31, 2026
- Business highlights accompanied quarterly results, with full details in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- CASGEVY revenue reached $43 million in Q1 2026, with more than 500 patients initiating treatment globally
- Cash, equivalents and marketable securities rose to $2,441.8 million, bolstered by $585.4 million convertible-note proceeds
AI summaries of CRSP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRSP
Don't miss the next CRSP filing
- Alerts as it files. A push when CRSP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRSP, by share count.
- Ask anything. An AI agent that reads every CRSP filing and answers with sources.
CRSP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| KASINGER JAMES R. | M | Sep 22, 2026 | 10,400 | - |
| KASINGER JAMES R. | Sell | Sep 22, 2026 | 10,400 | $60.24 |
| KASINGER JAMES R. | M | Sep 22, 2026 | 10,400 | $13.62 |
| Behbahani Ali | M | Sep 17, 2026 | 30,000 | - |
| Behbahani Ali | M | Sep 17, 2026 | 30,000 | $14.00 |
| Behbahani Ali | Sell | Sep 17, 2026 | 13,679 | $57.09 |
| Prasad Raju | G | Aug 7, 2026 | 750 | - |
| Fardis Maria | A | Jun 5, 2026 | 13,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $37.3M | $3.5M |
| Operating Income | - | -$466.6M | -$664.6M |
| Net Income | -$153.6M | -$366.3M | -$581.6M |
| Op. Margin | - | -1250.4% | -18933.6% |
| Net Margin | - | -981.5% | -16569.8% |
| Balance Sheet | |||
| Total Assets | $2.2B | $2.2B | $2.3B |
| Equity | - | $1.9B | $1.9B |
| ROE | - | -19.0% | -30.3% |
| Per Share | |||
| EPS | $-1.94 | $-4.34 | $-6.47 |
| Cash Flow | |||
| Operating CF | - | -$142.8M | -$345.0M |
| CapEx | $9.5M | $1.9M | $914K |
Source: XBRL data in CRISPR Therapeutics AG (CRSP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRSP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $1.92B |
| Q1 2026 | 32 | $1.63B |
| Q4 2025 | 32 | $1.80B |
| Q3 2025 | 33 | $2.32B |
| Q2 2025 | 33 | $1.59B |
| Q1 2025 | 27 | $826.7M |
| Q4 2024 | 21 | $775.3M |
| Q3 2024 | 20 | $660.9M |
- BlackRock+668.9K (+9%)
- Two Sigma Investments+505.6K (+34%)
- State Street Corp+339.2K (+9%)
- Morgan Stanley+211.8K (+32%)
- Bank of America Corp+172.0K (+17%)
- ARK Investment Management−1.85M (-16%)
- Dimensional Fund Advisors−218.8K (-44%)
- Goldman Sachs Group−141.8K (-34%)
- Citadel Advisors LLC−50.6K (-10%)
- FMR LLC (Fidelity)−46.2K (-2%)
- D.E. Shaw & Co+893.8K
- Allstate+8.0K
- StoneX Group Inc.+4.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRSP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| SC 13G | May 14, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 24, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CRSP SEC filings: frequently asked questions
Are CRSP insiders buying or selling?
In the last 90 days, CRISPR Therapeutics AG (CRSP) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.4 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRSP stock?
As of June 30, 2026, the largest CRISPR Therapeutics AG (CRSP) holders among the 13F filers tracked by SignalX were ARK Investment Management ($516.0 million), BlackRock ($455.4 million), State Street Corp ($235.7 million), Two Sigma Investments ($108.5 million), FMR LLC (Fidelity) ($104.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRSP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CRISPR Therapeutics AG (CRSP) reported revenue of $3.5 million (down 90.6% from FY2024) and a net loss of $581.6 million. Diluted EPS was -$6.47. The figures come from the XBRL data in the 10-K.
What are the main risks in CRSP's latest 10-K?
In the 10-K filed February 12, 2026, CRISPR Therapeutics AG (CRSP) flagged: Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data. Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position. (AI summary of the Risk Factors section.)
What did CRSP report in its latest 8-K?
CRISPR Therapeutics AG (CRSP) filed an 8-K on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). CRISPR Therapeutics reported financial results for quarter ended June 30, 2026.
What are the latest CRSP SEC filings?
CRISPR Therapeutics AG (CRSP) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on September 24, 2026.
What is CRSP's SEC CIK number?
CRISPR Therapeutics AG (CRSP)'s SEC Central Index Key (CIK) is 1674416. EDGAR lists every CRSP filing under that number.
Ask anything about CRSP
The research agent reads CRSP's filings, financials, insider trades and 13F holders, then answers with sources.